Skip Navigation



European Heart Journal Advance Access published online on October 19, 2008
European Heart Journal, doi:10.1093/eurheartj/ehn470
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/22/2703    most recent
ehn470v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Crespo-Leiro, M. G.
Right arrow Articles by Hermida-Prieto, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Crespo-Leiro, M. G.
Right arrow Articles by Hermida-Prieto, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Sirolimus treatment of left ventricular hypertrophy: who, and when?

Maria G. Crespo-Leiro1,* and Manuel Hermida-Prieto2

1 Heart Failure and Heart Transplantation Unit, Hospital Universitario A Coruña, La Coruña, Spain
2 Instituto de Ciencias de la Salud, Universidad de A Coruña, La Coruña, Spain

* Corresponding author. Tel: +34 981 178304, Fax: +34 981 178299, Email: Marisa_Crespo@canalejo.org

This editorial refers to ‘Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients’{dagger} by S.S. Kushwaha et al., on page 2742

The first 10% of the full text of this article appears below.

The protein known as mammalian target of rapamycin (mTOR) plays vital roles in protein synthesis, and hence in growth and cell proliferation, including the proliferation of immune response cells and neoplastic cells. The paths through which it acts have two main branches that start from mTOR complexes known as mTORC1/RAPTOR and mTORC2/RICTOR. The former is inhibited by sirolimus (rapamycin), everolimus, and their analogues, while the latter is not. Despite not inhibiting mTORC2/RICTOR, the sirolimus family are known collectively as mTOR inhibitors, and also as proliferation signal inhibitors (PSIs).1

mTOR inhibitors are attractive for post-transplantation therapy because their antiproliferative properties appear to combine immunosuppression . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients
Sudhir S. Kushwaha, Eugenia Raichlin, Yuri Sheinin, Walter K. Kremers, Krishnaswamy Chandrasekaran, Gregory J. Brunn, and Jeffrey L. Platt
EHJ 2008 29: 2742-2750. [Abstract] [FREE Full Text]